Paving the path to better understanding T-cell lymphomas: The importance of lymphoma registries

Abstract

Despite progresses in the field of non-Hodgkin lymphoma, therapy responses and outcomes remain poor for patients with T-cell lymphoma (TCL), especially for those with relapsed and refractory disease [ 1 , 2 ]. Factors such as marked disease heterogeneity, paucity of cases, and a distinct geographic distribution have limited the field's ability to make substantive and innovative advances. Perhaps, the most significant challenge is the absence of TCL-specific regimens, with CHOP-like chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) remaining as the standard of care for peripheral TCL (PTCL) in spite of high relapse rates [2] . Over the past decade, effort s have been made to identify clinical, epidemiologic, host/tumor genomic, and treatment factors that can have an impact on TCL outcomes and to improve survival. The Tcell project [3] ; the International Lymphoma Epidemiology Consortium (InterLymph) [4] ; the Lymphoma Epidemiology of Outcomes (LEO) [5] ; the Comprehensive Oncology Measures for PeripheraL T-cEll Lymphoma TrEatment (COMPLETE) [6] ; and the Latin American Group of Lymphoproliferative Disorders (GELL) [7] , are examples of these collaborative effort s developed in an attempt to answer relevant questions on the epidemiology, prognosis, and management of TCL.Using this approach, Yoon, Song, and Kim et al. present the results of the International Cooperative non-Hodgkin T-cell lymphoma (ICT) registry study, the first prospective registry of adult patients with TCL in Asia [8] . Thirty-two institutions from six Asian countries (Korea, China, Taiwan, Singapore, Malaysia, and Indonesia) enrolled patients aged 19 years and older diagnosed with neoplasms of mature T-and NK-cell according to the 2008 World Health Organization (WHO) classification. The objectives of the study were to estimate the relative frequencies, treatment approaches and outcomes of TCL across Asia. A total of

Case Report: An unclassified T cell lymphoma subtype with co-expression of TCR αβ and γ chains revealed by single cell sequencing

“…T cell lymphomas (TCL) contains a group of heterogeneous non-Hodgkin lymphomas (NHL) with T cell origins. Therapy responses and outcomes remain poor for patients with TCL due to the absence of TCL-specific regimens ( 1 , 2 ). In addition, TCL is highly heterogenous and contains over 40 subtypes according to 2022 WHO classification ( 3 ), making the diagnosis and treatment more challenging.…”